Inhaled Antibiotics Global Market Report 2024

The global inhaled antibiotics market has grown strongly in recent years. It will grow from $1.46 billion in 2023 to $1.58 billion in 2024 at a compound annual growth rate (CAGR) of 7.8%. The expansion observed in the historical period can be credited to various factors, including regulatory support and approvals, a transition from systemic to targeted delivery methods, an increase in antibiotic resistance, and a rise in respiratory infections.

The global inhaled antibiotics market is expected to see strong growth in the next few years. It will grow to $2.18 billion in 2028 at a compound annual growth rate (CAGR) of 8.4%. Anticipated growth in the forecast period can be attributed to several factors such as increased investments in research and development, a wider range of clinical applications, a growing emphasis on personalized medicine, advancements in drug formulations, and ongoing concerns regarding antibiotic resistance. Key trends expected in this period include sustained innovation in formulations, an approach centered around patients' needs, heightened research in respiratory health, a transition toward targeted therapies, and advancements in drug delivery systems.

The anticipated rise in respiratory diseases is poised to drive the growth of the inhaled antibiotics market. These conditions impair lung and airway function, affecting individuals' breathing. Inhaled antibiotics play a crucial role in enhancing lung function, staving off deterioration, extending periods between exacerbations, and improving the quality of life for patients with conditions like cystic fibrosis. Statistics reported by the Australian Institute of Health and Welfare revealed a notable increase in respiratory disease-related deaths in Australia in 2021, totaling 46,551. Similarly, data from The Lancet in September 2022 showcased a 9.50% rise in new cases of respiratory syncytial virus (RSV) during the 2021 summer, underscoring the escalating incidence of respiratory ailments that directly influences the inhaled antibiotics market.

The escalating demand within hospital settings is anticipated to propel the expansion of the inhaled antibiotics market. Hospitals, dedicated to providing medical care to the ill or injured, rely on inhaled antibiotics for managing respiratory infections. These medications help minimize disruptions to gut microbiota, customize treatment approaches, improve patient adherence, and reduce hospitalization rates. As per information from gov.wales in October 2022, NHS bed occupancy rose to 81.2% in 2021-22, marking an 11.8 percentage point increase from the previous year, indicative of the heightened reliance on healthcare facilities. This surge in hospital demand significantly influences the growth trajectory of inhaled antibiotics.

A prominent trend within the inhaled antibiotics market is the substantial investments directed towards their development. Pharmaceutical giants, exemplified by Enbiotix's $11 million investment in December 2021, are actively funding the development of antibiotics tailored for lung infections. These investments focus on clinical testing for medications like murepavadin and ColiFin, specifically targeting patients with cystic fibrosis (CF). Such initiatives underscore the commitment of major pharmaceutical entities towards advancing treatment options for respiratory ailments.

Innovative products like Breyna are being strategically introduced by major players in the inhaled antibiotics market to drive revenue growth. Breyna, an inhalation aerosol combining formoterol fumarate dihydrate and budesonide, effectively manages symptoms associated with asthma and persistent lung diseases. Viatris Inc., in partnership with Kindeva Drug Delivery L.P., successfully launched Breyna in July 2023. This FDA-approved generic version of AstraZeneca's Symbicort is supplied as a metered-dose inhaler and comes in two strengths, catering to patients' varying needs, reflecting the market's focus on innovation and tailored therapeutic solutions.

In August 2021, Philip Morris International Inc., a US-based tobacco company, acquired OtiTopic for an undisclosed sum. This acquisition aligns with PMI's strategic goal of broadening its portfolio of inhaled therapies and respiratory medication delivery. Utilizing its expertise, scientific knowledge, and inhalation capabilities beyond nicotine, PMI aims to expand its offerings in this domain. OtiTopic, a US-based respiratory drug development company specializing in inhaled antibiotics, now operates under the umbrella of Philip Morris International Inc.

Major companies operating in the inhaled antibiotics market report are Gilead Sciences Inc., Lupin Limited, Insmed Inc., Savara Inc., Joincare Pharmaceutical Group Industry Co. Ltd., Pharmaxis Ltd., Teva Pharmaceutical Industries Ltd., Raptor Pharmaceutical Corporation, Altan Pharma Limited, Cipla Limited, Maya Biotech Pvt. Ltd., Medisol Lifescience Pvt. Ltd., Nivon Specialties, Sentiss Pharma Pvt. Ltd., Ultratech India Limited, Midas Care Pharmaceuticals Pvt. Ltd., Precept Pharma Ltd., Luckys Pharma, Novartis AG, Bayer AG, Pfizer Inc., Grifols SA, Vertex Pharmaceuticals Inc., Aridis Pharmaceuticals, Bayer HealthCare, Nektar Therapeutics, Parion Sciences Inc., Zambon Group, Transave Inc., Alitair Pharmaceuticals, Synspira Therapeutics Inc., AIT Therapeutics Inc., Polyphor AG, Oppilan Pharma Ltd., OptiNose Inc.

North America was the largest region in the inhaled antibiotics market share in 2023. The regions covered in the inhaled antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhaled antibiotics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Diverse types of inhaled antibiotics are available, including aerosol or metered dose inhalers, dry powder formulations, sprays, and other variations. The metered-dose inhaler (MDI) stands as a frequently utilized device for delivering inhaled respiratory medications. These antibiotics find applications across a spectrum of respiratory conditions like pneumonia, asthma, bronchitis, among others, catering to the needs of hospitals and various other healthcare settings.

This report provides inhaled antibiotics market statistics, including inhaled antibiotics industry global market size, regional shares, competitors with an inhaled antibiotics market share, detailed inhaled antibiotics market segments, market trends and opportunities, and any further data you may need to thrive in the inhaled antibiotics industry. This inhaled antibiotics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhaled antibiotics market consists of sales of jet nebulizers, ultrasonic nebulizers, mesh inhalers, and soft mist inhalers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.